A Phase 3 Extension Study of Ataluren (PTC124) in Subjects With Nonsense-Mutation-Mediated Cystic Fibrosis.
Phase of Trial: Phase III
Latest Information Update: 17 Dec 2017
At a glance
- Drugs Ataluren (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions; Registrational
- Sponsors PTC Therapeutics
- 10 Jun 2017 Biomarkers information updated
- 01 Mar 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 Apr 2014 New trial record